(GuruFocus, November 15, 2009) Investment Guru Seth Klarman has been busy buying distressed debt nowadays and he might just ignored stocks. For the third quarter, he purchase two stocks:
No. 1: Enzon Inc. (ENZN, Financial), Buy: 1.51% of the portfolio - Total: 2,071,382 Shares
Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics to treat patients with cancer and adjacent diseases. Enzon's specialized sales force markets ABELCET, ONCASPAR, ADAGEN, and DEPOCYT in the United States. In addition, Enzon also receives royalties on sales of PEG-INTRON, marketed by Schering-Plough Corporation, and MACUGEN, marketed by OSI Pharmaceuticals and Pfizer Inc. Enzon's product-driven strategy includes an extensive drug development program that leverages its proprietary technologies, including a Customized Linker Technology PEGylation platform that utilizes customized linkers designed to release compounds at a controlled rate. Enzon also utilizes contract manufacturing opportunities to broaden its revenue base and enhance its organizational productivity. Enzon complements its internal research and development efforts with strategic initiatives. Enzon Inc. has a market cap of $448.4 million; its shares were traded at around $9.88 with and P/S ratio of 2.3.
No. 2: ViaSat Inc. (VSAT, Financial), Add: 4.27% of the portfolio - Total: 3,046,516 Shares
ViaSat Inc. designs, produces and markets advanced digital satellitetelecommunications and other networking and signal processing equipment. The company has been developing and marketing its technology through strategic alliances for emerging commercial markets, such as private corporate networks, mobile applications, alternative carrier access and broadband Internet/Intranet access by satellite to multiple servers. Viasat Inc. has a market cap of $937.4 million; its shares were traded at around $29.65 with a P/E ratio of 21.1 and P/S ratio of 1.5. Viasat Inc. had an annual average earning growth of 18.9% over the past 5 years.
GuruFocus provides real time information and insights of Investment Gurus such as Warren Buffett and Seth Klarman for Premium Members. If you are not a premium member, click here to sign up or upgrade. 7-Day Free Trial is available.
No. 1: Enzon Inc. (ENZN, Financial), Buy: 1.51% of the portfolio - Total: 2,071,382 Shares
Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics to treat patients with cancer and adjacent diseases. Enzon's specialized sales force markets ABELCET, ONCASPAR, ADAGEN, and DEPOCYT in the United States. In addition, Enzon also receives royalties on sales of PEG-INTRON, marketed by Schering-Plough Corporation, and MACUGEN, marketed by OSI Pharmaceuticals and Pfizer Inc. Enzon's product-driven strategy includes an extensive drug development program that leverages its proprietary technologies, including a Customized Linker Technology PEGylation platform that utilizes customized linkers designed to release compounds at a controlled rate. Enzon also utilizes contract manufacturing opportunities to broaden its revenue base and enhance its organizational productivity. Enzon complements its internal research and development efforts with strategic initiatives. Enzon Inc. has a market cap of $448.4 million; its shares were traded at around $9.88 with and P/S ratio of 2.3.
No. 2: ViaSat Inc. (VSAT, Financial), Add: 4.27% of the portfolio - Total: 3,046,516 Shares
ViaSat Inc. designs, produces and markets advanced digital satellitetelecommunications and other networking and signal processing equipment. The company has been developing and marketing its technology through strategic alliances for emerging commercial markets, such as private corporate networks, mobile applications, alternative carrier access and broadband Internet/Intranet access by satellite to multiple servers. Viasat Inc. has a market cap of $937.4 million; its shares were traded at around $29.65 with a P/E ratio of 21.1 and P/S ratio of 1.5. Viasat Inc. had an annual average earning growth of 18.9% over the past 5 years.
GuruFocus provides real time information and insights of Investment Gurus such as Warren Buffett and Seth Klarman for Premium Members. If you are not a premium member, click here to sign up or upgrade. 7-Day Free Trial is available.
